On January 1, Masoud Khayyami will take over as interim CEO of SpectraCure AB. Masoud will stay in the role until the recruitment process for a new CEO has been completed. He is currently a board member of SpectraCure and has previously been CEO of the company.
"I feel confident with Masoud stepping in as interim CEO during our recruitment process as he is well-versed in the business. It gives the company continuity and stability until a new CEO is in place. The recruitment process for the CEO is ongoing and will be completed during the spring," says SpectraCure's board chairman Jörgen Wennberg.
For further information:
Jörgen Wennberg, Chairman of the Board
E-mail: jorgen.k.wennberg@icloud.com
Website: www.spectracure.com
SpectraCure is developing a treatment system for the elimination of internal solid cancer tumors. We are initially focusing on recurrent prostate cancer, with the hope of being able to treat other cancers such as primary prostate cancer, breast cancer, pancreatic cancer, and head and neck cancer in the future. The approach is based on a proprietary and patented treatment system, Q-PRO®, consisting of a hardware device, a laser unit, which performs PDT treatment and treats the prostate itself, combined with a software device, the patented IDOSE® dose planning platform. The method allows the laser light dose to be controlled so that the tumour is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to make interstitial PDT treatment accurate, precise, safe for every patient. The goal is that in addition to being tumor free, the patient will be able to maintain their quality of life, with limited side effects. We are conducting clinical trials as an important part of the continued development of the company's treatment system.
The company is listed in the Premier segment of the Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, and trades under the short name SPEC.
